# Nobuyuki Hashimoto

> Nobuyuki Hashimoto is a Series B investor at Taiho Ventures backing Medical. See 1 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2)
- Total investments: 1
- Last investment: Sep 2016
- Lead investor: 0%
- Last updated: Oct 2026

Nobuyuki Hashimoto is an Investment Committee Member at Taiho Ventures. He is also the Global Chief Corporate Officer, Board Member, and Executive Director at Taiho Pharmaceutical.

## Contacts

5 contacts available for Nobuyuki Hashimoto: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/nobuyuki-hashimoto?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Health Care | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Arcus Biosciences | Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant(AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio.Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen. | $70M | Series B | Sep 01, 2016 | http://www.arcusbio.com |

1 of 1 investments shown.

## Co-investors
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 1 deal together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 1 deal together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 1 deal together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 1 deal together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 1 deal together
- [Novartis](https://shizune.co/investors/profile/novartis) — VC Fund, 1 deal together

## About Taiho Ventures

VC Fund · California City, United States

Taiho Ventures is a company that specializes in the research and development of pharmaceuticals.

2 contacts available at Taiho Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Sakae Asanuma | Founding President and CEO | https://shizune.co/investors/profile/sakae-asanuma |
| Nobuyuki Hashimoto | Investment Committee Member | https://shizune.co/investors/profile/nobuyuki-hashimoto |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Nobuyuki Hashimoto invest in?

Nobuyuki Hashimoto invests primarily in Medical, Health Care and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Nobuyuki Hashimoto?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Nobuyuki Hashimoto last invest?

The most recent investment recorded for Nobuyuki Hashimoto closed in Sep 2016. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co